These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19581499)

  • 1. Tumor necrosis factor-alpha--converting enzyme roles in hypertension-induced hypertrophy: look both ways when crossing the street.
    Zamilpa R; Chilton RJ; Lindsey ML
    Hypertension; 2009 Sep; 54(3):471-2. PubMed ID: 19581499
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor necrosis factor-alpha-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis.
    Wang X; Oka T; Chow FL; Cooper SB; Odenbach J; Lopaschuk GD; Kassiri Z; Fernandez-Patron C
    Hypertension; 2009 Sep; 54(3):575-82. PubMed ID: 19581512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of Nox4 promotes angiotensin II-induced epidermal growth factor receptor activation and subsequent cardiac hypertrophy by increasing ADAM17 expression.
    Zeng SY; Chen X; Chen SR; Li Q; Wang YH; Zou J; Cao WW; Luo JN; Gao H; Liu PQ
    Can J Cardiol; 2013 Oct; 29(10):1310-9. PubMed ID: 23850346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE.
    Odenbach J; Wang X; Cooper S; Chow FL; Oka T; Lopaschuk G; Kassiri Z; Fernandez-Patron C
    Hypertension; 2011 Jan; 57(1):123-30. PubMed ID: 21079048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy.
    Wang X; Chow FL; Oka T; Hao L; Lopez-Campistrous A; Kelly S; Cooper S; Odenbach J; Finegan BA; Schulz R; Kassiri Z; Lopaschuk GD; Fernandez-Patron C
    Circulation; 2009 May; 119(18):2480-9. PubMed ID: 19398663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS.
    Patel VB; Clarke N; Wang Z; Fan D; Parajuli N; Basu R; Putko B; Kassiri Z; Turner AJ; Oudit GY
    J Mol Cell Cardiol; 2014 Jan; 66():167-76. PubMed ID: 24332999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion.
    Xiao LJ; Lin P; Lin F; Liu X; Qin W; Zou HF; Guo L; Liu W; Wang SJ; Yu XG
    Int J Oncol; 2012 May; 40(5):1714-24. PubMed ID: 22200661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transactivated EGFR mediates α₁-AR-induced STAT3 activation and cardiac hypertrophy.
    Li Y; Zhang H; Liao W; Song Y; Ma X; Chen C; Lu Z; Li Z; Zhang Y
    Am J Physiol Heart Circ Physiol; 2011 Nov; 301(5):H1941-51. PubMed ID: 21856923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II downregulates ACE2-mediated enhancement of MMP-2 activity in human cardiofibroblasts.
    Kuan TC; Chen MY; Liao YC; Ko L; Hong YH; Yen CY; Hsieh WY; Cheng KS; Wu CL; Lin CS
    Biochem Cell Biol; 2013 Dec; 91(6):435-42. PubMed ID: 24219285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of epidermal growth factor receptor and endoplasmic reticulum stress in vascular remodeling induced by angiotensin II.
    Takayanagi T; Kawai T; Forrester SJ; Obama T; Tsuji T; Fukuda Y; Elliott KJ; Tilley DG; Davisson RL; Park JY; Eguchi S
    Hypertension; 2015 Jun; 65(6):1349-55. PubMed ID: 25916723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DKK3 overexpression attenuates cardiac hypertrophy and fibrosis in an angiotensin-perfused animal model by regulating the ADAM17/ACE2 and GSK-3β/β-catenin pathways.
    Zhai CG; Xu YY; Tie YY; Zhang Y; Chen WQ; Ji XP; Mao Y; Qiao L; Cheng J; Xu QB; Zhang C
    J Mol Cell Cardiol; 2018 Jan; 114():243-252. PubMed ID: 29196099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD38 promotes angiotensin II-induced cardiac hypertrophy.
    Guan XH; Hong X; Zhao N; Liu XH; Xiao YF; Chen TT; Deng LB; Wang XL; Wang JB; Ji GJ; Fu M; Deng KY; Xin HB
    J Cell Mol Med; 2017 Aug; 21(8):1492-1502. PubMed ID: 28296029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular ADAM17 as a Novel Therapeutic Target in Mediating Cardiovascular Hypertrophy and Perivascular Fibrosis Induced by Angiotensin II.
    Takayanagi T; Forrester SJ; Kawai T; Obama T; Tsuji T; Elliott KJ; Nuti E; Rossello A; Kwok HF; Scalia R; Rizzo V; Eguchi S
    Hypertension; 2016 Oct; 68(4):949-955. PubMed ID: 27480833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into the activity, differential expression, mutual regulation, and functions of matrix metalloproteinases and a disintegrin and metalloproteinases in hypertension and cardiac disease.
    Berry E; Bosonea AM; Wang X; Fernandez-Patron C
    J Vasc Res; 2013; 50(1):52-68. PubMed ID: 23172306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II-induced hypertension and cardiac hypertrophy are differentially mediated by TLR3- and TLR4-dependent pathways.
    Singh MV; Cicha MZ; Nunez S; Meyerholz DK; Chapleau MW; Abboud FM
    Am J Physiol Heart Circ Physiol; 2019 May; 316(5):H1027-H1038. PubMed ID: 30793936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted overexpression of transmembrane tumor necrosis factor provokes a concentric cardiac hypertrophic phenotype.
    Dibbs ZI; Diwan A; Nemoto S; DeFreitas G; Abdellatif M; Carabello BA; Spinale FG; Feuerstein G; Sivasubramanian N; Mann DL
    Circulation; 2003 Aug; 108(8):1002-8. PubMed ID: 12912811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A disintegrin and metalloproteinase 12 prevents heart failure by regulating cardiac hypertrophy and fibrosis.
    Nakamura Y; Kita S; Tanaka Y; Fukuda S; Obata Y; Okita T; Kawachi Y; Tsugawa-Shimizu Y; Fujishima Y; Nishizawa H; Miyagawa S; Sawa Y; Sehara-Fujisawa A; Maeda N; Shimomura I
    Am J Physiol Heart Circ Physiol; 2020 Feb; 318(2):H238-H251. PubMed ID: 31774689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy.
    Asakura M; Kitakaze M; Takashima S; Liao Y; Ishikura F; Yoshinaka T; Ohmoto H; Node K; Yoshino K; Ishiguro H; Asanuma H; Sanada S; Matsumura Y; Takeda H; Beppu S; Tada M; Hori M; Higashiyama S
    Nat Med; 2002 Jan; 8(1):35-40. PubMed ID: 11786904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the ectodomain-releasing protease ADAM17 is directly regulated by the osteosarcoma and bone-related transcription factor RUNX2.
    Araya HF; Sepulveda H; Lizama CO; Vega OA; Jerez S; Briceño PF; Thaler R; Riester SM; Antonelli M; Salazar-Onfray F; Rodríguez JP; Moreno RD; Montecino M; Charbonneau M; Dubois CM; Stein GS; van Wijnen AJ; Galindo MA
    J Cell Biochem; 2018 Nov; 119(10):8204-8219. PubMed ID: 29923217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.
    Geng L; Wang W; Chen Y; Cao J; Lu L; Chen Q; He R; Shen W
    Exp Mol Pathol; 2010 Aug; 89(1):72-81. PubMed ID: 20621845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.